CEO Kessler Acknowledges ‘Disappointing’ Q3 As Prescription Business Divested
• By David Wallace
Generate a summary of this article
Listen to this article
Perrigo CEO Murray Kessler has acknowledged “disappointing” third quarter results for the company during a transitional quarter that saw it finally divest its Rx prescription generics business ahead of its upcoming acquisition of consumer healthcare specialist HRA Pharma.
Perrigo says goodbye to the Rx business as it waits to absorb HRA • Source: Alamy
Perrigo CEO Murray Kessler has insisted that the company has a “bright future” despite acknowledging “disappointing third quarter results [that] reflect the continuing impacts of the challenging operating environment caused by the global COVID-19 pandemic.”
[Sidebar#GB151066]
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.